Chinmay Maheshwari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chinmay Maheshwari has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ciro Isidoro
Laboratory of Molecular Pathology, Department of Health Sciences, Università del Piemonte Orientale “A. Avogadro”, Via Solaroli 17, 28100 Novara, Italy
9 shared publications - Alessandra Ferraresi
Laboratory of Molecular Pathology, Department of Health Sciences, Università del Piemonte Orientale “A. Avogadro”, Via Solaroli 17, 28100 Novara, Italy
7 shared publications - Danny N. Dhanasekaran
Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA, USA
6 shared publications - Chiara Vidoni
Laboratory of Molecular Pathology, Department of Health Sciences, Università del Piemonte Orientale, via Solaroli 17, 28100 Novara, Italy, Italy
3 shared publications - Letizia Vallino
Laboratory of Molecular Pathology, Department of Health Sciences, Università del Piemonte Orientale “A. Avogadro”, Via Solaroli 17, 28100 Novara, Italy
3 shared publications - Uthman Walusimbi
Laboratory of Molecular Pathology, Department of Health Sciences, Università del Piemonte Orientale, via Solaroli 17, 28100 Novara, Italy, Italy
3 shared publications
Latest Publications
- 25 September 2026
- Published by Elsevier in Cancer Letters
- Vol. 661
LncRNAs and the cancer epitranscriptome: Mechanisms and therapeutic potential
- 25 September 2026
- Published by Elsevier in Cancer Letters
- Vol. 661
LncRNAs and the cancer epitranscriptome: Mechanisms and therapeutic potential
- Open Access
- 12 February 2026
- Published by MDPI AG in Preprints.org
PTEN Dephosphorylates BECLIN-1 to Regulate Serum-Dependent Autophagy in Thyroid Cancer Cells
PTEN is a well-established tumor suppressor that plays a central role in the regulation of cell growth, metabolism, and survival. As a protein-lipid dual phosphatase, PTEN negatively regulates the PI3K/AKT signaling pathway, which in turn modulates autophagy, a conserved catabolic process that allows cells to degrade and recycle intracellular components, through the downstream effector mTORC1. While this represents the canonical mechanism by which PTEN influences autophagy, here we show that PTEN also regulates autophagy through an alternative, AKT-independent pathway. Specifically, through genetic manipulations of PTEN expression in thyroid cancer cells, we identify BECLIN-1 as a direct target of PTEN protein phosphatase activity. PTEN physically associates with BECLIN-1 under both basal and nutrient-deprived conditions, promoting its dephosphorylation at serine 295, thus relieving AKT inhibition resulting in autophagy activation. This regulatory event correlates with increased autophagic flux under starvation, as reflected by enhanced LC3 I to LC3 II conversion. Importantly, BECLIN-1 dephosphorylation is mediated by PTEN protein phosphatase activity and does not require its lipid phosphatase function. Furthermore, bioinformatic analyses reveal that high PTEN expression, together with enhanced autophagic activity (MAP1LC3B), is associated with improved clinical outcome in cancer patients. These findings uncover a direct, AKT-independent mechanism by which PTEN controls autophagy by modulating BECLIN-1 phosphorylation status. Together, our results provide novel insight into how PTEN coordinates cellular adaptation to metabolic stress and highlight an additional pathway through which PTEN regulates the autophagic machinery in cancer cells.
- 12 February 2026
- Published by MDPI AG in Preprints.org
Open AccessPTEN Dephosphorylates BECLIN-1 to Regulate Serum-Dependent Autophagy in Thyroid Cancer Cells
PTEN is a well-established tumor suppressor that plays a central role in the regulation of cell growth, metabolism, and survival. As a protein-lipid dual phosphatase, PTEN negatively regulates the PI3K/AKT signaling pathway, which in turn modulates autophagy, a conserved catabolic process that allows cells to degrade and recycle intracellular components, through the downstream effector mTORC1. While this represents the canonical mechanism by which PTEN influences autophagy, here we show that PTEN also regulates autophagy through an alternative, AKT-independent pathway. Specifically, through genetic manipulations of PTEN expression in thyroid cancer cells, we identify BECLIN-1 as a direct target of PTEN protein phosphatase activity. PTEN physically associates with BECLIN-1 under both basal and nutrient-deprived conditions, promoting its dephosphorylation at serine 295, thus relieving AKT inhibition resulting in autophagy activation. This regulatory event correlates with increased autophagic flux under starvation, as reflected by enhanced LC3 I to LC3 II conversion. Importantly, BECLIN-1 dephosphorylation is mediated by PTEN protein phosphatase activity and does not require its lipid phosphatase function. Furthermore, bioinformatic analyses reveal that high PTEN expression, together with enhanced autophagic activity (MAP1LC3B), is associated with improved clinical outcome in cancer patients. These findings uncover a direct, AKT-independent mechanism by which PTEN controls autophagy by modulating BECLIN-1 phosphorylation status. Together, our results provide novel insight into how PTEN coordinates cellular adaptation to metabolic stress and highlight an additional pathway through which PTEN regulates the autophagic machinery in cancer cells.
- Open Access
- 25 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9380
The Biological Role and Clinical Significance of BECLIN-1 in Cancer
BECLIN-1 is a multidomain protein that, through dynamic interaction with a variety of partners, controls autophagy and apoptosis, two processes dysregulated in cancer cells, thus playing a crucial role in cell fate. Although mutations in the BECN1 gene are rare in cancer, its frequent monoallelic deletion contributes to spontaneous cancer initiation by impairing autophagy, establishing it as a haploinsufficient tumor suppressor gene. The expression and activity of BECLIN-1 are further modulated by epigenetic mechanisms, alternative splicing, post-translational modifications, and alternative partner interactions. These layers of regulation critically affect the autophagy response, with an impact on cell proliferation, motility, and resistance to multiple stress stimuli. In this review article we outline the structural and functional properties of BECLIN-1 and discuss how its altered expression and protein–protein interactions can be harnessed for diagnostic and therapeutic purposes in cancer.
- 25 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9380
Open AccessThe Biological Role and Clinical Significance of BECLIN-1 in Cancer
BECLIN-1 is a multidomain protein that, through dynamic interaction with a variety of partners, controls autophagy and apoptosis, two processes dysregulated in cancer cells, thus playing a crucial role in cell fate. Although mutations in the BECN1 gene are rare in cancer, its frequent monoallelic deletion contributes to spontaneous cancer initiation by impairing autophagy, establishing it as a haploinsufficient tumor suppressor gene. The expression and activity of BECLIN-1 are further modulated by epigenetic mechanisms, alternative splicing, post-translational modifications, and alternative partner interactions. These layers of regulation critically affect the autophagy response, with an impact on cell proliferation, motility, and resistance to multiple stress stimuli. In this review article we outline the structural and functional properties of BECLIN-1 and discuss how its altered expression and protein–protein interactions can be harnessed for diagnostic and therapeutic purposes in cancer.
- Open Access
- 29 July 2025
- Published by MDPI AG in Preprints.org
The Biological Role and Clinical Significance of BECLIN-1 in Cancer
BECLIN-1 is a multidomain protein that through dynamic interaction with a variety of partners controls autophagy and apoptosis, two processes dysregulated in cancer cells, thus playing a crucial role in cell destiny. Mutations of BECN1 gene have not been described, yet its monoallelic deletion leads to insufficient autophagy with an impact on spontaneous cancer development, which identifies it as a haploinsufficient tumor suppressor gene. Epigenetic modulation of its expression, along with alternative splicing, post-translational modifications and alternative partner interactions influence its regulation of autophagy, thus affecting cancer cell behavior in terms of proliferation, motility, and survival under stress. In this review article we describe the structural and functional properties of BECLIN-1 and discuss how its altered expression and interaction with other proteins in cancer cells can be harnessed for diagnostic and therapeutic purposes.
- 29 July 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Biological Role and Clinical Significance of BECLIN-1 in Cancer
BECLIN-1 is a multidomain protein that through dynamic interaction with a variety of partners controls autophagy and apoptosis, two processes dysregulated in cancer cells, thus playing a crucial role in cell destiny. Mutations of BECN1 gene have not been described, yet its monoallelic deletion leads to insufficient autophagy with an impact on spontaneous cancer development, which identifies it as a haploinsufficient tumor suppressor gene. Epigenetic modulation of its expression, along with alternative splicing, post-translational modifications and alternative partner interactions influence its regulation of autophagy, thus affecting cancer cell behavior in terms of proliferation, motility, and survival under stress. In this review article we describe the structural and functional properties of BECLIN-1 and discuss how its altered expression and interaction with other proteins in cancer cells can be harnessed for diagnostic and therapeutic purposes.
- Open Access
- 27 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (21) , 11527
High Mitophagy and Low Glycolysis Predict Better Clinical Outcomes in Acute Myeloid Leukemias
Acute myeloid leukemia (AML) emerges as one of the most common and fatal leukemias. Treatment of the disease remains highly challenging owing to profound metabolic rewiring mechanisms that confer plasticity to AML cells, ultimately resulting in therapy resistance. Autophagy, a highly conserved lysosomal-driven catabolic process devoted to macromolecular turnover, displays a dichotomous role in AML by suppressing or promoting disease development and progression. Glycolytic metabolism represents a pivotal strategy for AML cells to sustain increasing energy needs related to uncontrolled growth during disease progression. In this study, we tested the hypothesis that a high glycolytic rate and low autophagy flux could represent an advantage for AML cell proliferation and thus be detrimental for patient’s prognosis, and vice versa. TCGA in silico analysis of the AML cohort shows that the high expression of MAP1LC3B (along with that of BECN1 and with low expression of p62/SQSTM1) and the high expression of BNIP3 (along with that of PRKN and of MAP1LC3B), which together are indicative of increased autophagy and mitophagy, correlate with better prognosis. On the other hand, the high expression of glycolytic markers HK2, PFKM, and PKM correlates with poor prognosis. Most importantly, the association of a low expression of glycolytic markers with a high expression of autophagy–mitophagy markers conferred the longest overall survival for AML patients. Transcriptomic analysis showed that this combined signature correlates with the downregulation of a subset of genes required for the differentiation of myeloid cells, lactate/pyruvate transporters, and cell cycle progression, in parallel with the upregulation of genes involved in autophagy/lysosomal trafficking and proteolysis, anti-tumor responses like beta-interferon production, and positive regulation of programmed cell death. Taken together, our data support the view that enhanced autophagy-mitophagy flux together with low glycolytic rate predisposes AML patients to a better clinical outcome, suggesting that autophagy inducers and glucose restrictors may hold potential as adjuvant therapeutics for improving AML management.
- 27 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (21) , 11527
Open AccessHigh Mitophagy and Low Glycolysis Predict Better Clinical Outcomes in Acute Myeloid Leukemias
Acute myeloid leukemia (AML) emerges as one of the most common and fatal leukemias. Treatment of the disease remains highly challenging owing to profound metabolic rewiring mechanisms that confer plasticity to AML cells, ultimately resulting in therapy resistance. Autophagy, a highly conserved lysosomal-driven catabolic process devoted to macromolecular turnover, displays a dichotomous role in AML by suppressing or promoting disease development and progression. Glycolytic metabolism represents a pivotal strategy for AML cells to sustain increasing energy needs related to uncontrolled growth during disease progression. In this study, we tested the hypothesis that a high glycolytic rate and low autophagy flux could represent an advantage for AML cell proliferation and thus be detrimental for patient’s prognosis, and vice versa. TCGA in silico analysis of the AML cohort shows that the high expression of MAP1LC3B (along with that of BECN1 and with low expression of p62/SQSTM1) and the high expression of BNIP3 (along with that of PRKN and of MAP1LC3B), which together are indicative of increased autophagy and mitophagy, correlate with better prognosis. On the other hand, the high expression of glycolytic markers HK2, PFKM, and PKM correlates with poor prognosis. Most importantly, the association of a low expression of glycolytic markers with a high expression of autophagy–mitophagy markers conferred the longest overall survival for AML patients. Transcriptomic analysis showed that this combined signature correlates with the downregulation of a subset of genes required for the differentiation of myeloid cells, lactate/pyruvate transporters, and cell cycle progression, in parallel with the upregulation of genes involved in autophagy/lysosomal trafficking and proteolysis, anti-tumor responses like beta-interferon production, and positive regulation of programmed cell death. Taken together, our data support the view that enhanced autophagy-mitophagy flux together with low glycolytic rate predisposes AML patients to a better clinical outcome, suggesting that autophagy inducers and glucose restrictors may hold potential as adjuvant therapeutics for improving AML management.
- Open Access
- 29 July 2024
- Published by MDPI AG in Preprints.org
High LETM1 Expression Associates with Impaired Mitophagy and Bad Prognosis in Diffuse Large B-cell Lymphomas and Acute Myeloid Leukemias
Leucine zipper-EF-hand containing transmembrane protein 1 (LETM1) is a mitochondrial inner membrane protein involved in mitochondrial morphology and homeostasis. LETM1 is highly expressed in many human solid cancers and correlates with poor prognosis possibly due to mitochondrial dysfunction. However, the functional role of LETM1 in the progression of hematological malignancies remains to be elucidated. In this study, we found that higher LETM1 expression was associated with a short overall survival in Diffuse Large B-Cell Lymphoma (DLBCL) and in Acute Myeloid Leukemias (AML) patients. The transcriptomic analysis showed that LETM1 expression is positively correlated with oncogenic pathways (e.g., glucose transport, stem cell maintenance, mTOR and Wnt signaling pathways, mitotic G2/M phase transition, and cell proliferation) and negatively correlated with autophagy-related processes and apoptosis. In contrast, low expression of LETM1 associated with upregulation of BECLIN-1-dependent mitophagy, which in turn improves the prognosis in both DLBCL and AML patients. Our data suggest that LETM1 is a valuable prognostic marker and a possible therapeutic target for improving the clinical outcome in hematological malignancies.
- 29 July 2024
- Published by MDPI AG in Preprints.org
Open AccessHigh LETM1 Expression Associates with Impaired Mitophagy and Bad Prognosis in Diffuse Large B-cell Lymphomas and Acute Myeloid Leukemias
Leucine zipper-EF-hand containing transmembrane protein 1 (LETM1) is a mitochondrial inner membrane protein involved in mitochondrial morphology and homeostasis. LETM1 is highly expressed in many human solid cancers and correlates with poor prognosis possibly due to mitochondrial dysfunction. However, the functional role of LETM1 in the progression of hematological malignancies remains to be elucidated. In this study, we found that higher LETM1 expression was associated with a short overall survival in Diffuse Large B-Cell Lymphoma (DLBCL) and in Acute Myeloid Leukemias (AML) patients. The transcriptomic analysis showed that LETM1 expression is positively correlated with oncogenic pathways (e.g., glucose transport, stem cell maintenance, mTOR and Wnt signaling pathways, mitotic G2/M phase transition, and cell proliferation) and negatively correlated with autophagy-related processes and apoptosis. In contrast, low expression of LETM1 associated with upregulation of BECLIN-1-dependent mitophagy, which in turn improves the prognosis in both DLBCL and AML patients. Our data suggest that LETM1 is a valuable prognostic marker and a possible therapeutic target for improving the clinical outcome in hematological malignancies.
- Open Access
- 23 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 5691
Ovarian Cancer Cell-Conditioning Medium Induces Cancer-Associated Fibroblast Phenoconversion through Glucose-Dependent Inhibition of Autophagy
One aspect of ovarian tumorigenesis which is still poorly understood is the tumor–stroma interaction, which plays a major role in chemoresistance and tumor progression. Cancer-associated fibroblasts (CAFs), the most abundant stromal cell type in the tumor microenvironment, influence tumor growth, metabolism, metastasis, and response to therapy, making them attractive targets for anti-cancer treatment. Unraveling the mechanisms involved in CAFs activation and maintenance is therefore crucial for the improvement of therapy efficacy. Here, we report that CAFs phenoconversion relies on the glucose-dependent inhibition of autophagy. We show that ovarian cancer cell-conditioning medium induces a metabolic reprogramming towards the CAF-phenotype that requires the autophagy-dependent glycolytic shift. In fact, 2-deoxy-D-glucose (2DG) strongly hampers such phenoconversion and, most importantly, induces the phenoreversion of CAFs into quiescent fibroblasts. Moreover, pharmacological inhibition (by proline) or autophagy gene knockdown (by siBECN1 or siATG7) promotes, while autophagy induction (by either 2DG or rapamycin) counteracts, the metabolic rewiring induced by the ovarian cancer cell secretome. Notably, the nutraceutical resveratrol (RV), known to inhibit glucose metabolism and to induce autophagy, promotes the phenoreversion of CAFs into normal fibroblasts even in the presence of ovarian cancer cell-conditioning medium. Overall, our data support the view of testing autophagy inducers for targeting the tumor-promoting stroma as an adjuvant strategy to improve therapy success rates, especially for tumors with a highly desmoplastic stroma, like ovarian cancer.
- 23 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 5691
Open AccessOvarian Cancer Cell-Conditioning Medium Induces Cancer-Associated Fibroblast Phenoconversion through Glucose-Dependent Inhibition of Autophagy
One aspect of ovarian tumorigenesis which is still poorly understood is the tumor–stroma interaction, which plays a major role in chemoresistance and tumor progression. Cancer-associated fibroblasts (CAFs), the most abundant stromal cell type in the tumor microenvironment, influence tumor growth, metabolism, metastasis, and response to therapy, making them attractive targets for anti-cancer treatment. Unraveling the mechanisms involved in CAFs activation and maintenance is therefore crucial for the improvement of therapy efficacy. Here, we report that CAFs phenoconversion relies on the glucose-dependent inhibition of autophagy. We show that ovarian cancer cell-conditioning medium induces a metabolic reprogramming towards the CAF-phenotype that requires the autophagy-dependent glycolytic shift. In fact, 2-deoxy-D-glucose (2DG) strongly hampers such phenoconversion and, most importantly, induces the phenoreversion of CAFs into quiescent fibroblasts. Moreover, pharmacological inhibition (by proline) or autophagy gene knockdown (by siBECN1 or siATG7) promotes, while autophagy induction (by either 2DG or rapamycin) counteracts, the metabolic rewiring induced by the ovarian cancer cell secretome. Notably, the nutraceutical resveratrol (RV), known to inhibit glucose metabolism and to induce autophagy, promotes the phenoreversion of CAFs into normal fibroblasts even in the presence of ovarian cancer cell-conditioning medium. Overall, our data support the view of testing autophagy inducers for targeting the tumor-promoting stroma as an adjuvant strategy to improve therapy success rates, especially for tumors with a highly desmoplastic stroma, like ovarian cancer.
- Open Access
- 2 August 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (8) , 1069
Isolation, Characterization, and Autophagy Function of BECN1-Splicing Isoforms in Cancer Cells
Alternative splicing allows the synthesis of different protein variants starting from a single gene. Human Beclin 1 (BECN1) is a key autophagy regulator that acts as haploinsufficient tumor suppressor since its decreased expression correlates with tumorigenesis and poor prognosis in cancer patients. Recent studies show that BECN1 mRNA undergoes alternative splicing. Here, we report on the isolation and molecular and functional characterization of three BECN1 transcript variants (named BECN1-α, -β and -γ) in human cancer cells. In ovarian cancer NIHOVCAR3, these splicing variants were found along with the canonical wild-type. BECN1-α lacks 143 nucleotides at its C-terminus and corresponds to a variant previously described. BECN1-β and -γ lack the BCL2 homology 3 domain and other regions at their C-termini. Following overexpression in breast cancer cells MDA-MB231, we found that BECN1-α stimulates autophagy. Specifically, BECN1-α binds to Parkin and stimulates mitophagy. On the contrary, BECN1-β reduces autophagy with a dominant negative effect over the endogenous wild-type isoform. BECN1-γ maintains its ability to interact with the vacuolar protein sorting 34 and only has a slight effect on autophagy. It is possible that cancer cells utilize the alternative splicing of BECN1 for modulating autophagy and mitophagy in response to environmental stresses.
- 2 August 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (8) , 1069
Open AccessIsolation, Characterization, and Autophagy Function of BECN1-Splicing Isoforms in Cancer Cells
Alternative splicing allows the synthesis of different protein variants starting from a single gene. Human Beclin 1 (BECN1) is a key autophagy regulator that acts as haploinsufficient tumor suppressor since its decreased expression correlates with tumorigenesis and poor prognosis in cancer patients. Recent studies show that BECN1 mRNA undergoes alternative splicing. Here, we report on the isolation and molecular and functional characterization of three BECN1 transcript variants (named BECN1-α, -β and -γ) in human cancer cells. In ovarian cancer NIHOVCAR3, these splicing variants were found along with the canonical wild-type. BECN1-α lacks 143 nucleotides at its C-terminus and corresponds to a variant previously described. BECN1-β and -γ lack the BCL2 homology 3 domain and other regions at their C-termini. Following overexpression in breast cancer cells MDA-MB231, we found that BECN1-α stimulates autophagy. Specifically, BECN1-α binds to Parkin and stimulates mitophagy. On the contrary, BECN1-β reduces autophagy with a dominant negative effect over the endogenous wild-type isoform. BECN1-γ maintains its ability to interact with the vacuolar protein sorting 34 and only has a slight effect on autophagy. It is possible that cancer cells utilize the alternative splicing of BECN1 for modulating autophagy and mitophagy in response to environmental stresses.
- Open Access
- 30 December 2021
- Published by Korean Society of Cancer Prevention in Journal of Cancer Prevention
- Vol. 26 (4) , 224-236
Calorie Restriction for Cancer Prevention and Therapy: Mechanisms, Expectations, and Efficacy
Chiara Vidoni, Alessandra Ferraresi, Andrea Esposito, Chinmay Maheshwari, Danny N. Dhanasekaran, Vincenzo Mollace, Ciro Isidoro. J Cancer Prev 2021;26:224-36. https://doi.org/10.15430/JCP.2021.26.4.224
- 30 December 2021
- Published by Korean Society of Cancer Prevention in Journal of Cancer Prevention
- Vol. 26 (4) , 224-236
Open AccessCalorie Restriction for Cancer Prevention and Therapy: Mechanisms, Expectations, and Efficacy
Chiara Vidoni, Alessandra Ferraresi, Andrea Esposito, Chinmay Maheshwari, Danny N. Dhanasekaran, Vincenzo Mollace, Ciro Isidoro. J Cancer Prev 2021;26:224-36. https://doi.org/10.15430/JCP.2021.26.4.224